Taplin ME - Search Results

1

Drug insight: role of the androgen receptor in the development and progression of prostate cancer.

Taplin ME. Taplin ME. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. doi: 10.1038/ncponc0765. Nat Clin Pract Oncol. 2007. PMID: 17392714 Review.

2

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Taplin ME, et al. N Engl J Med. 1995 May 25;332(21):1393-8. doi: 10.1056/NEJM199505253322101. N Engl J Med. 1995. PMID: 7723794

3

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.

Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ. Joyce R, et al. Among authors: taplin me. J Urol. 1998 Jan;159(1):149-53. doi: 10.1016/s0022-5347(01)64039-4. J Urol. 1998. PMID: 9400459

4

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Taplin ME, et al. Cancer Res. 1999 Jun 1;59(11):2511-5. Cancer Res. 1999. PMID: 10363963

5

A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.

Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N. Savarese D, et al. Among authors: taplin me. Semin Oncol. 1999 Oct;26(5 Suppl 17):39-44. Semin Oncol. 1999. PMID: 10604268 Clinical Trial.

6

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ. Savarese DM, et al. Among authors: taplin me. J Clin Oncol. 2001 May 1;19(9):2509-16. doi: 10.1200/JCO.2001.19.9.2509. J Clin Oncol. 2001. PMID: 11331330 Clinical Trial.

7

Clinical review 134: The endocrinology of prostate cancer.

Taplin ME, Ho SM. Taplin ME, et al. J Clin Endocrinol Metab. 2001 Aug;86(8):3467-77. doi: 10.1210/jcem.86.8.7782. J Clin Endocrinol Metab. 2001. PMID: 11502765 Review. No abstract available.

8

Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.

Taplin ME, Bubley GJ, Rajeshkumar B, Shuster T, Ko YJ, Morganstern DE. Taplin ME, et al. Semin Oncol. 2001 Aug;28(4 Suppl 15):32-9. doi: 10.1016/s0093-7754(01)90152-6. Semin Oncol. 2001. PMID: 11685726 Clinical Trial.

9

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B Study 9663. Taplin ME, et al. J Clin Oncol. 2003 Jul 15;21(14):2673-8. doi: 10.1200/JCO.2003.11.102. J Clin Oncol. 2003. PMID: 12860943 Clinical Trial.

10

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.

Taplin ME, Balk SP. Taplin ME, et al. J Cell Biochem. 2004 Feb 15;91(3):483-90. doi: 10.1002/jcb.10653. J Cell Biochem. 2004. PMID: 14755679 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results